Literature DB >> 15854791

Behavior and corpus callosum morphology relationships in velocardiofacial syndrome (22q11.2 deletion syndrome).

Kevin M Antshel1, Jena Conchelos, Gabrielle Lanzetta, Wanda Fremont, Wendy R Kates.   

Abstract

Velocardiofacial syndrome (VCFS) is a neurodevelopmental disorder caused by a microdeletion on chromosome 22q11.2 that predisposes affected individuals to learning disabilities and psychiatric conditions. Previous research has indicated that compared with comparison children, children with VCFS have larger corpus callosal areas. Children with VCFS are often diagnosed with comorbid attention deficit hyperactivity disorder (ADHD), and previous research has indicated that children with ADHD often have smaller corpus callosal areas than controls. The present study investigated two hypotheses: children with VCFS would have larger callosal areas than controls, and children with VCFS+ADHD would have smaller callosal areas than children with VCFS. Corpus callosum area was obtained from the mid-sagittal slice and was assessed in children with VCFS (n=60) and age- and gender-matched control participants (n=52). Results indicated that all of the corpus callosum measures were significantly different between the two groups except for the genu. Across all measures, children with VCFS demonstrated a larger corpus callosum area. Within the VCFS sample, children with VCFS+ADHD (n=30) had smaller total callosal, splenium, and genu areas than children with VCFS alone. Although children with VCFS+ADHD had smaller total callosal areas than children with VCFS, relative to control participants, these children had larger total callosal and subregion areas except for the genu. In addition to other anatomic anomalies, corpus callosal abnormalities appear to be another variable to consider when analyzing brain/behavior relations in this population.

Entities:  

Mesh:

Year:  2005        PMID: 15854791     DOI: 10.1016/j.pscychresns.2005.02.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  29 in total

Review 1.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

Review 2.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

3.  Corpus callosum morphology and ventricular size in chromosome 22q11.2 deletion syndrome.

Authors:  Alexei M C Machado; Tony J Simon; Vy Nguyen; Donna M McDonald-McGinn; Elaine H Zackai; James C Gee
Journal:  Brain Res       Date:  2006-12-13       Impact factor: 3.252

Review 4.  Neural phenotypes of common and rare genetic variants.

Authors:  Carrie E Bearden; David C Glahn; Agatha D Lee; Ming-Chang Chiang; Theo G M van Erp; Tyrone D Cannon; Allan L Reiss; Arthur W Toga; Paul M Thompson
Journal:  Biol Psychol       Date:  2008-02-23       Impact factor: 3.251

5.  White matter microstructural abnormalities of the cingulum bundle in youths with 22q11.2 deletion syndrome: associations with medication, neuropsychological function, and prodromal symptoms of psychosis.

Authors:  Wendy R Kates; Amy K Olszewski; Matthew H Gnirke; Zora Kikinis; Joshua Nelson; Kevin M Antshel; Wanda Fremont; Petya D Radoeva; Frank A Middleton; Martha E Shenton; Ioana L Coman
Journal:  Schizophr Res       Date:  2014-07-25       Impact factor: 4.939

Review 6.  Bridging the gene-behavior divide through neuroimaging deletion syndromes: Velocardiofacial (22q11.2 Deletion) and Williams (7q11.23 Deletion) syndromes.

Authors:  Daniel Paul Eisenberg; Mbemba Jabbi; Karen Faith Berman
Journal:  Neuroimage       Date:  2010-03-03       Impact factor: 6.556

7.  White matter abnormalities in 22q11.2 deletion syndrome: preliminary associations with the Nogo-66 receptor gene and symptoms of psychosis.

Authors:  Matthew D Perlstein; Moeed R Chohan; Ioana L Coman; Kevin M Antshel; Wanda P Fremont; Matthew H Gnirke; Zora Kikinis; Frank A Middleton; Petya D Radoeva; Martha E Shenton; Wendy R Kates
Journal:  Schizophr Res       Date:  2013-12-08       Impact factor: 4.939

Review 8.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

9.  Evidence of gray matter reduction and dysfunction in chromosome 22q11.2 deletion syndrome.

Authors:  Vandana Shashi; Thomas R Kwapil; Jessica Kaczorowski; Margaret N Berry; Cesar S Santos; Timothy D Howard; Dhruman Goradia; Konasale Prasad; Diwadkar Vaibhav; Rajaprabhakaran Rajarethinam; Edward Spence; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2010-01-30       Impact factor: 3.222

10.  Regional cortical volumes and congenital heart disease: a MRI study in 22q11.2 deletion syndrome.

Authors:  Marie Schaer; Bronwyn Glaser; Marie-Christine Ottet; Maude Schneider; Meritxell Bach Cuadra; Martin Debbané; Jean-Philippe Thiran; Stephan Eliez
Journal:  J Neurodev Disord       Date:  2010-09-14       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.